Skip to main content

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland Oct. 23, 2017.

Arnd Wiegmann/Reuters

New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India’s Aurobindo Pharma Ltd for up to $1 billion.

The deal, which comes after price pressure hurt the U.S. pills business, includes some 300 products. An initial $900 million cash payment could be followed by $100 million in performance-based payments to the Basel-based drugmaker.

This transaction has been in the works for months but some analysts said Aurobindo was paying less than they had penciled in for the deal.

Story continues below advertisement

Shares in Aurobindo rose more than 9 percent on the news, while Novartis stock was up 0.2 percent at 1000 GMT.

“The acquisition announced today is in line with our strategy to grow and diversify our business in the U.S.,” said N Govindarajan, managing director of Aurobindo, adding the deal will make it the second-largest U.S. generics maker by prescriptions. http://bit.ly/2MRmXqA

Aurobindo will get plants in Wilson, North Carolina, as well as in Hicksville and Melville, New York, Novartis said.

Around 750 employees as well as field representatives from the PharmaDerm branded dermatology business are expected to transfer to Aurobindo.

Narasimhan, who became CEO on Feb. 1, has pushed ahead with efforts to slim down Novartis that began under his predecessor, Joe Jimenez, to focus on higher-margin drugs.

He sold a consumer health joint venture to GlaxoSmithKline this year for $13 billion and plans to spin off his Alcon eyecare unit in 2019.

The U.S. Sandoz pills business has long been a problem child for Novartis, with price pressure hurting results and becoming a main reason the division has pared back its growth targets, most recently in July.

Story continues below advertisement

“Through this transaction, we are refocusing our business,” said Richard Francis, the Sandoz division head, adding the disposal would allow him to focus on products such as biosimilars, or near-copies of rival’s biological drug blockbusters whose patents have expired.

Analyst Stefan Schneider at Swiss bank Vontobel said the lackluster $900 million up-front price showed just how deep the U.S. pills business and dermatology assets had fallen.

“We had assumed a price of 1 times sales for such a transaction,” Schneider said. “We realize that pricing pressure in the U.S. generics market is greater that we had anticipated, as last year’s revenues were $1.5 billion for this business and first-half 2018 revenues only $0.6 billion.”

He has a “hold” rating on the shares.

Narasimhan, a U.S. citizen and Harvard-trained doctor, has so far said that Sandoz businesses elsewhere including in Europe remain core parts of Novartis. Overall, Sandoz had nearly $5 billion in sales in the first half.

Following this transaction, the Sandoz U.S. portfolio will include biosimilars as well as complex generics such as its Glatopa copy of Teva’s Copaxone medicine for relapsing multiple sclerosis.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter